Opportunities Among Uncertainties

APR 16 2020

 
 

This time we invited Dr. Jingsong Wang, Founder, Chairman & CEO at Harbour BioMed to share his views on how his company has been facing and overcoming the challenges and hurdles, meanwhile seeking a new way to maintain stable performance in both finance and clinical progress during this trying period of ‘Global Pandemic’.

Moderater:

Invited guests:

About Harbour BioMed:

Harbour BioMed is a global biopharmaceutical company established in 2016, developing innovative therapeutics in the fields of immuno-oncology and immunological diseases and using its two patented transgenic mice platforms generating fully human monoclonal antibodies to co-discover and co-develop with strategic collaborators. In 2019, HBM received the Clarivate Analytics Top APAC Pharmaceutical Innovator Award, CNPIC’s Top 10 Private Companies with Highest Investment Value and was awarded by EY-Fudan as an Enterprises with Highest Growth Potential. Furthermore, HBM was honored as Hurun China Future Unicorns in 2019 Q1 & Q2.

For more information, please visit here.